Cordis has launched the SELUTION Global Coronary Registry, a 10,000-patient study tracking real-world outcomes for its Selution SLR drug-eluting balloon (DEB) across multiple continents.
The registry will monitor patients for up to five years, building on five ongoing randomized trials, including the SUCCESS PTA study, which confirmed the device’s sustained safety and efficacy in complex peripheral artery disease.
Cordis acquired the Selution SLR technology from MedAlliance in 2023 for $1.135 billion, positioning it at the forefront of coronary DEB innovation. The company says early data shows the balloon performs comparably to paclitaxel-eluting benchmarks, with added safety benefits.
Chief Medical Officer Dr. George Adams stated, “This registry reflects our commitment to delivering robust clinical evidence that puts patients first.”
Follow MEDWIRE.AI for updates on coronary device research and clinical trials.
